Affordable Access

Publisher Website

Cdk5 deregulation in the pathogenesis of Alzheimer's disease

Authors
Publisher
Elsevier Ltd
Publication Date
Volume
10
Issue
9
Identifiers
DOI: 10.1016/j.molmed.2004.07.001
Disciplines
  • Biology
  • Medicine

Abstract

The aberrant metabolism of tau and β-amyloid precursor protein (APP) has key roles in the neurodegenerative processes that contribute to the etiology of Alzheimer's disease (AD). These pathological characteristics of AD have recently been linked to the deregulation of cyclin-dependent kinase 5 (cdk5). The finding that the inducible expression of p25, which is the neurotoxic activator of cdk5, triggers progressive neurodegeneration and neurofibrillary tangle formation in mice provides compelling evidence that p25–cdk5 is one of the crucial pathways that can lead to AD pathophysiology. Furthermore, a role for cdk5 in modulating APP processing and β-amyloid generation is emerging. Therefore, as one of the molecular links between APP and tau, cdk5 might be a valuable target for therapeutic intervention in AD and other neurodegenerative diseases.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Cdk5 deregulation in the pathogenesis of Alzheimer...

on Trends in Molecular Medicine September 2004

Cdk5 as a drug target for the treatment of Alzheim...

on Journal of molecular neuroscie... December 2002

Cdk5, a therapeutic target for Alzheimer's disease...

on Biochimica et Biophysica Acta... Jan 01, 2004

Cdk5, a therapeutic target for Alzheimer's disease...

on Biochimica et Biophysica Acta Mar 11, 2004
More articles like this..